RecruitingNCT06783127
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
Sponsor
Santa Chiara Hospital
Enrollment
3,000 participants
Start Date
Jan 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Eligibility
Sex: MALE
Inclusion Criteria1
- BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
Exclusion Criteria1
- Olaparib treatment in a clinical trial
Interventions
DRUGOlaparib
Olaparib given according the clinical practice to BRCA positive mCRPC patients
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06783127
Related Trials
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT020646731 location